Navigation Links
New Approach to Celiac Testing Identifies More Patients at Risk
Date:8/27/2013

CAMBRIDGE, Mass., Aug. 27, 2013 /PRNewswire/ -- Researchers have developed a new approach to detecting unrecognized cases of celiac disease in the community, revealing this immune disorder is far more common than previously recognized.

In a study of more than 2500 adults, the researchers combined traditional antibody testing (measuring the immune response to gluten) with an assessment of specific genetic risk markers. They found that more than half of the subjects had genetic risk factors for developing celiac disease. This newly developed testing strategy also showed that celiac disease potentially affected at least one in 60 women and one in 80 men. The research is published online today in the journal BMC Medicine.

One of the researchers, Dr. Jason Tye-Din from the Walter and Eliza Hall Institute, who also leads the Celiac Clinic at The Royal Melbourne Hospital, said the study indicated that the combination of a genetic test with a panel of antibody tests should increase the accuracy of diagnosis, decrease overall medical costs by reducing invasive diagnostic tests, and avoid medically unnecessary use of a gluten-free diet.

"Currently, bowel biopsies are recommended for anybody with positive antibody tests," Dr. Tye-Din said. "In this study, the inclusion of a simple genetic test helped identify a substantial number of people whose antibody tests were falsely positive and who did not actually require a bowel biopsy to test for the possibility of celiac disease."

Celiac disease is caused by an inappropriate immune response to dietary gluten. Gluten can be found in wheat, rye, barley and oats. When gluten is consumed, it can cause a wide range of complaints from chronic tiredness, iron deficiency, osteoporosis, itchy rash, and headaches to various digestive symptoms. Celiac disease damages the lining of the small intestine and can lead to significant medical complications such as autoimmune disease, infertility, liver failure and cancer. Celiac disease usually develops in childhood and is life-long, but early diagnosis and treatment can reduce the risk of adverse health complications.

Conservative estimates using an older antibody test had previously suggested the number of Australians with celiac disease as no more than one in 100. Findings in this study now suggest that the prevalence of celiac disease in the U.S. population, which is estimated to be one in 133 on the basis of antibody testing alone, may need to be re-evaluated.

Dr. Tye-Din in collaboration with Dr. Bob Anderson, chief scientific officer at ImmusanT, worked with Barwon Health, Deakin University, Healthscope Pathology and the University of Queensland Diamantina Institute to develop and trial the new diagnostic approach.

"Accurate and timely diagnosis of celiac disease is important for the health of patients who are managing the disease. Making a diagnosis based on a blood test alone or starting a gluten-free diet without a confirmatory test is insufficient and can impose an unnecessary and very restrictive exclusion diet for the rest of a person's life," said Dr. Anderson. "Given the life-long impact of a diagnosis of celiac disease, ensuring a definitive diagnosis is crucial. This study provides a strategy to improve the diagnosis of celiac disease in the community by combining the benefits of antibody and genetic testing before proceeding to biopsy."

The research was supported by INOVA Diagnostics Inc; ImmusanT, which acquired the assets of Nexpep Pty. Ltd; the National Health and Medical Research Council; the Victorian Health Promotion Foundation; the Geelong Region Medical Research Foundation; and the Victorian government.

ImmusanT Contact:
Leslie J. Williams, President & CEO
(617) 299-8399, ext. 201
Leslie@ImmusanT.com

ImmusanT Media Contact:
Canale Communications
Pam Lord
(619) 849-6003
pam@canalecomm.com

Walter and Eliza Hall Institute Media Contact:
Vanessa Solomon, Communications Adviser
+61 3 9345 2971
+61 431766715
solomon@wehi.edu.au 


'/>"/>
SOURCE ImmusanT Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. CPhI Pharma Evolution to Address Practical Approaches to Process Analytical Technology in Interactive Interview with PAT Expert
2. DMC Harper University Hospital Dialysis Access Center Introduces A Safer, Longer-Lasting Approach to "Vascular Graft" Procedure
3. Coalition Letter Opposes Anti-Life U.S. Senate S.959, as Floor Vote Approaches
4. Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases
5. Partnership Formed to Explore Personalized Medicine Approach for Amyotrophic Lateral Sclerosis (ALS) Treatments
6. SynteractHCR Addressing Successful Ways to Approach Sponsor and CRO Collaboration at May Pharmaceutical Events in US and Europe
7. Healthcares First Direct Contracting Market Launches Today; Will Offer Mutually Beneficial Approach for Hospitals and Suppliers
8. Study Showcases Effective Approaches for Evaluating the Performance of Executives who Handle Managed Markets Accounts
9. Deadline Approaches for ISPE Drug Shortage Survey
10. Pit Crew Approach with Real-Time CPR Feedback Saves Lives
11. Janssen Neuroscientists and Colleagues Challenge Healthcare Industry to Create Integrated Approaches to Healthcare Innovation in Newly Published Article
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016   Pulmatrix, Inc ., ... developing innovative inhaled drugs, announced today that it was ... Investments reconstituted its comprehensive set of U.S. and ... "This is an important milestone for Pulmatrix," said Chief ... shareholder awareness of our progress in developing drugs for ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... - Forecast to 2022" report to their offering. ... for the patients with kidney failure, it replaces the function ... the patient,s blood and thus the treatment helps to keep ... in balance. Increasing number of ESRD patients ...
(Date:6/23/2016)... June 23, 2016 Roche (SIX: RO, ROG; ... for its Elecsys BRAHMS PCT (procalcitonin) assay as a ... septic shock. With this clearance, Roche is the first ... integrated solution for sepsis risk assessment and management. ... infection and PCT levels in blood can aid clinicians ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... 2016 , ... The temporary closing of Bruton Memorial Library on June 21 due to a ... new, often overlooked aspect of head lice: the parasite’s ability to live away from a ... occurrence, but a necessary one in the event that lice have simply gotten out of ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van ... Wellness at Work award to iHire in recognition of their exemplary accomplishments in worksite ... 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum ...
(Date:6/24/2016)... ... ... was in a crisis. Her son James, eight, was out of control. Prone to extreme ... “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If there was ... other children and say he was going to kill them. If we were driving ...
(Date:6/24/2016)... Rhinebeck, NY (PRWEB) , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of ... of companies that call for a minimum wage raise to $12 an hour by 2020 ... wage. This will restore the lost value of the minimum wage, assure the wage floor ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... actively feeding the Frederick area economy by obtaining investment capital for emerging technology ... past 2½ years that have already resulted in more than a million dollars ...
Breaking Medicine News(10 mins):